Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, July 2001, p. 2157-2159, Vol. 45, No. 7
Department of Clinical Research, Singapore
General Hospital, Singapore 169608,1
Division of Medical Sciences, National Cancer Centre,
Singapore 169610,2 and Department of
Infectious Diseases, Tan Tock Seng Hospital, Singapore
308433,3 Singapore
Received 11 December 2000/Returned for modification 13 February
2001/Accepted 26 April 2001
Novel mutations in NADH dehydrogenase (ndh) were
detected in 8 of 84 (9.5%) isoniazid (INH)-resistant isolates (T110A
[n = 1], R268H [n = 7]), but not
in 22 INH-susceptible isolates of Mycobacterium
tuberculosis. Significantly, all eight isolates with mutations at
ndh did not have mutations at katG, kasA, or the promoter regions of inhA or ahpC, except
for one isolate. Mutations in ndh appear to be an
additional molecular mechanism for isoniazid resistance in M. tuberculosis.
Resistance to isoniazid (INH) in
Mycobacterium tuberculosis is attributed to mutations in
several genes. The katG gene, which encodes
catalase-peroxidase, is the gene most commonly altered, with the
majority of mutations occurring at codon 315 (1, 9, 13).
Mutations in the promoter regions of inhA (9, 13, 17) and oxyR-ahpC genes (2, 15) have
been identified in INH-resistant strains but not INH-susceptible
strains. Four independent mutations were also reported to be found in
the kasA gene of INH-resistant M. tuberculosis
strains (7), but recent work showed that three of these
four mutations are found in INH-susceptible isolates as well (3,
10). The common arginine-to-leucine substitution in codon 463 of
the katG gene is now thought to be a polymorphism, as this
amino acid substitution is detectable in both susceptible and resistant
strains (4, 9).
Determination of drug resistance in M. tuberculosis
routinely takes 3 to 8 weeks as the clinical samples need to be
cultured. In order to hasten this process, targeted molecular
approaches have been done in Europe and the United States (9,
17). In Spain, molecular analysis of part of the coding sequence
of katG and the promoter regions of inhA and
ahpC was shown to be effective in detecting resistance in
87% of INH-resistant isolates (17). A previous study used
a similar strategy, targeting four genes: katG, kasA, and
the promoter regions of inhA and ahpC
(3). Results showed, however, that 36% of the Singaporean
isolates had no detectable alterations at these genes, suggesting that other molecular mechanisms may be in play (3).
Recently, a new mechanism for INH resistance in Mycobacterium
smegmatis has been identified (8). Mutations in the
ndh gene, encoding an NADH dehydrogenase, caused defects in
the enzyme activity that resulted in an increased NADH/NAD+
ratio and coresistance to isoniazid and ethionamide. This mechanism has
not been previously reported for M. tuberculosis. In the
present study, 84 INH-resistant and 22 INH-susceptible M. tuberculosis isolates have been screened for mutations in
the ndh gene in order to assess if NADH dehydrogenase
defects contribute to isoniazid resistance in M. tuberculosis isolates in Singapore.
Consecutive isoniazid-resistant M. tuberculosis isolates
were collected from the Central Tuberculosis Laboratory from August 1994 to December 1996. Drug susceptibility testing was done using the
BACTEC 460 radiometric method (Becton Dickinson, Towson, Md.), and the
isoniazid concentration was 0.1 µg/ml. Eighty-four M. tuberculosis isolates monoresistant to INH, none of which were multidrug resistant, and 22 INH-susceptible isolates were analyzed.
Amplification of the codon 315 region of the katG gene,
promoter regions of the inhA and ahpC genes, and
the entire kasA gene was performed as previously described
(3). The entire ndh gene was studied by
amplifying five overlapping fragments using the PCR primers shown in
Table 1. The PCR products were purified (QIAquick PCR purification kit or QIAquick gel extraction kit; QIAGEN)
and directly sequenced using the BigDye Terminators sequencing kit and
the ABI PRISM 377 automated sequencer (PE Biosystems, Branchburg,
N.J.). Isolates with mutations were reamplified and resequenced in
order to confirm the results.
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.7.2157-2159.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Novel Mutations in ndh in
Isoniazid-Resistant Mycobacterium tuberculosis
Isolates
![]()
ABSTRACT
Top
Abstract
Text
References
![]()
TEXT
Top
Abstract
Text
References
TABLE 1.
Oligonucleotide primer sequences for the amplification of
the entire ndh genea
Mutations in the ndh gene were detected in 8 (9.5%) of the 84 INH-resistant isolates (T110A [n = 1] and R268H [n = 7]). The T110A mutation was present in the second PCR fragment, and the R268H mutation was present in the third. Neither of these mutations was detected in any of the 22 INH-susceptible isolates. Seven of the eight isolates with these mutations did not have any other detectable molecular alterations at other known target genes for INH resistance.
The 84 INH-resistant isolates have previously been screened also for
mutations or deletions at the katG gene, mutations in the
promoter regions of the inhA and ahpC-oxyR genes,
and mutations in the kasA gene (3). Table
2 shows the results of the genotypic analysis for these genes as well as for the ndh gene. Of the
eight isolates with mutations in the ndh gene, seven did not
have any mutations at any of the other targeted regions screened, and
one isolate (R268H in ndh) also had a mutation in the
ahpC gene at T51.
|
DNA fingerprinting of the eight isolates with mutations in the ndh gene was done using IS6110 restriction fragment length polymorphism typing (18) and the recently described minisatellite-based typing (6, 16). The isolate with the T110A mutation had a 16-band IS6110 fingerprint, while the seven isolates with the R268H alteration had single 1.4-kb band IS6110 fingerprint. Minisatellite-based typing showed that these eight isolates were unrelated except for two isolates with the R268H alteration.
The mutations detected in the present study occur at positions which
differ from those of previously published mutations of the
ndh gene in M. smegmatis (Fig.
1) (8). The amino acid
positions 110 and 268 are conserved in mycobacteria but not in
Escherichia coli and Synechocystis spp.
(8). These amino acids are not within the NAD and flavin
adenine dinucleotide binding domains.
|
The mechanism for INH resistance in M. tuberculosis isolates with ndh mutations is likely an increase in the NADH/NAD+ ratios in the M. tuberculosis cells as was shown for M. smegmatis (8). These higher levels of NADH might competitively inhibit the binding of the INH-NAD adduct to the active site of the InhA enzyme (12, 14). Alternatively, since NADH is a substrate for the peroxidases AhpCF and KatG (5, 11), increased concentrations of NADH may competitively inhibit the peroxidation of INH by KatG (8). Miesel et al. have proposed that an increase in the NADH concentration prevents the action of INH and ethionamide which act in conjunction to confer high-level resistance (8).
Seven of the eight (87.5%) isolates had the same mutation (R268H) in the ndh gene. Rapid screening of mutations at this position may be possible for isolates from other geographical regions such as the United States and Europe, in order to determine the prevalence of this mutation in these areas and possibly add to the targeted approach for the detection of INH resistance.
In contrast, in Singapore a targeted approach for the identification of INH resistance with five genes detected genotypic changes in only 63% of the M. tuberculosis isolates. Further work is needed to fully elucidate alternative molecular mechanisms for INH resistance in M. tuberculosis.
In conclusion, this is the first report of the detection of novel mutations in the ndh gene in INH-resistant M. tuberculosis isolates. The data suggest an additional molecular mechanism for INH resistance.
| |
ACKNOWLEDGMENTS |
|---|
We acknowledge the Central Tuberculosis Laboratory, Department of Pathology, Singapore General Hospital, for providing isolates. We thank Lynn L. H. Tang and Irene H. K. Lim for excellent technical assistance and are grateful to the Clinical Research Unit, Tan Tock Seng Hospital, for administrative support.
This work was supported by a grant from the National Medical Research Council of Singapore (grant NMRC/329/1999).
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Division of Medical Sciences, National Cancer Centre, Republic of Singapore 169610. Phone: 65-436 8313. Fax: 65-372 0161. E-mail: dmslsg{at}nccs.com.sg.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Heym, B., P. M. Alzari, N. Honore, and S. T. Cole. 1995. Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol. Microbiol. 15:235-245[Medline]. |
| 2. | Kelley, C. L., D. A. Rouse, and S. L. Morris. 1997. Analysis of ahpC gene mutations in isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 41:2057-2058[Abstract]. |
| 3. |
Lee, A. S. G.,
I. H. K. Lim,
L. L. H. Tang,
A. Telenti, and S. Y. Wong.
1999.
Contribution of kasA analysis to detection of isoniazid-resistant Mycobacterium tuberculosis in Singapore.
Antimicrob. Agents Chemother.
43:2087-2089 |
| 4. | Lee, A. S. G., L. L. H. Tang, I. H. K. Lim, M. L. Ling, L. Tay, and S. Y. Wong. 1997. Lack of clinical significance for the common arginine-to-leucine substitution at codon 463 of the katG gene in isoniazid-resistant Mycobacterium tuberculosis in Singapore. J. Infect. Dis. 176:1125-1126[Medline]. |
| 5. |
Marcinkeviciene, J. A.,
R. S. Magliozzo, and J. S. Blanchard.
1995.
Purification and characterization of the Mycobacterium smegmatis catalase-peroxidase involved in isoniazid activation.
J. Biol. Chem.
270:22290-22295 |
| 6. |
Mazars, E.,
S. Lesjean,
A.-L. Banuls,
M. Gilbert,
V. Vincent,
B. Gicquel,
M. Tibayrenc,
C. Locht, and P. Supply.
2001.
High-resolution minisatellite-based typing as a portable approach to global analysis of Mycobacterium tuberculosis molecular epidemiology.
Proc. Natl. Acad. Sci. USA
98:1901-1906 |
| 7. |
Mdluli, K.,
R. A. Slayden,
Y. Q. Zhu,
S. Ramaswamy,
X. Pan,
D. Mead,
D. D. Crane,
J. M. Musser, and C. E. Barry, III.
1998.
Inhibition of a Mycobacterium tuberculosis -ketoacyl ACP synthase by isoniazid.
Science
280:1607-1610 |
| 8. |
Miesel, L.,
T. R. Weisbrod,
J. A. Marcinkeviciene,
R. Bittman, and W. R. Jacobs.
1998.
NADH dehydrogenase defects confer isoniazid resistance and conditional lethality in Mycobacterium smegmatis.
J. Bacteriol.
180:2459-2467 |
| 9. | Musser, J. M., V. Kapur, D. L. Williams, B. N. Kreiswirth, D. van Soolingen, and J. D. A. van Embden. 1996. Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. J. Infect. Dis. 173:196-202[Medline]. |
| 10. |
Piatek, A. S.,
A. Telenti,
M. R. Murray,
H. El-Hajj,
W. R. Jacobs,
F. R. Kramer, and D. Alland.
2000.
Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing.
Antimicrob. Agents Chemother.
44:103-110 |
| 11. | Poole, L. B., and H. R. Ellis. 1996. Flavin-dependent alkyl hydroperoxide reductase from Salmonella typhimurium. 1. Purification and enzymatic activities of overexpressed AhpF and AhpC proteins. Biochemistry 35:56-64[CrossRef][Medline]. |
| 12. | Quemard, A., J. C. Sacchettini, A. Dessen, C. Vilcheze, R. Bittman, W. R. Jacobs, Jr., and J. S. Blanchard. 1995. Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis. Biochemistry 34:8235-8241[CrossRef][Medline]. |
| 13. | Rouse, D. A., Z. M. Li, G. H. Bai, and S. L. Morris. 1995. Characterization of the katG and inhA genes of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 39:2472-2477[Abstract]. |
| 14. |
Rozwarski, D. A.,
G. A. Grant,
D. H. R. Barton,
W. R. Jacobs, Jr., and J. C. Sacchettini.
1998.
Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis.
Science
279:98-102 |
| 15. | Sreevatsan, S., X. Pan, Y. Zhang, V. Deretic, and J. M. Musser. 1997. Analysis of oxyR-ahpC region in isoniazid-resistant and -susceptible Mycobacterium tuberculosis complex organisms recovered from diseased humans and animals in diverse localities. Antimicrob. Agents Chemother. 41:600-606[Abstract]. |
| 16. | Supply, P., E. Mazars, S. Lesjean, V. Vincent, B. Gicquel, and C. Locht. 2000. Variable human minisatellite-like regions in the Mycobacterium tuberculosis genome. Mol. Microbiol. 36:762-771[CrossRef][Medline]. |
| 17. | Telenti, A., N. Honore, C. Bernasconi, J. March, A. Ortega, B. Heym, H. E. Takiff, and S. T. Cole. 1997. Genotypic assessment of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level. J. Clin. Microbiol. 35:719-723[Abstract]. |
| 18. |
Van Embden, J. D.,
M. D. Cave,
J. T. Crawford,
J. W. Dale,
K. D. Eisenach,
B. Gicquel,
P. Hermans,
C. Martin,
R. McAdam,
T. M. Shinnick, and P. M. Small.
1993.
Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology.
J. Clin. Microbiol.
31:406-409 |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |